CTCs isolated from prostate cancer patients can express PSA and show molecular characteristics of prostate cancer such as AR copy number gain, PTEN loss and TMPRSS2-ETS gene fusion [83]. This evidence concerns the gene TMPRSS2 and prostate carcinoma.